In a recent clinical trial, Pfizer announced that its experimental weight loss drug PF-08653944 demonstrated promising results. The study, which is currently in its Phase 2b stage, indicated that patients maintained consistent weight loss without reaching a plateau by week 28. This suggests that continued effectiveness may persist through week 64 and beyond. Of the 108 participants involved in the trial, side effects were primarily mild or moderate, with only one case of severe nausea reported. However, 10 patients did discontinue treatment due to adverse effects. Pfizer's Chief Internal Medicine Officer, Dr. Jim List, expressed confidence in the drug's efficacy and plans to incorporate a higher maintenance dose into the upcoming Phase 3 study. The weight loss market is competitive, as other companies like Amgen and Eli Lilly are also testing their own weight loss drugs. Amgen's MareTide is currently in several Phase 3 trials, while Eli Lilly has reported success with its drug retatrutide, which has shown greater weight loss effectiveness in trials. Pfizer acquired Metsera, the developer of PF-08653944, after a bidding war with Novo Nordisk, highlighting the strong competition in the industry. Overall, Pfizer's entry into the weight loss drug market comes with challenges, but their recent trial results indicate they may have a viable option to compete with existing therapies.